FDA clears inHeart ’s digital twin of the heart
France-based medical device developer inHeart has received clearance from the U.S. Food and Drug Administration (FDA) for its AI-driven digital twin of the heart.
The company’s AI software module offers interactive 3D models of the heart generated by AI that analyzes preprocedural CT or MR images. The technology has been proven useful in preplanning ventricular tachycardia ablations, a treatment for a type of irregular heartbeat, the company said.
While the software has been commercially available to clinicians in Europe, FDA clearance now allows inHEART to market the product to hospitals across the U.S. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 19, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Idiopathic fascicular ventricular tachycardia in a pediatric patient with suicidal ideation and self-injurious behavior - Uchefuna MA, Eletta RY, Delgado A, Beker S.
We present the case of a 10-year-old female child, with no pertinent medical history... (Source: SafetyLit)
Source: SafetyLit - January 10, 2024 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Severe traumatic brain injury presenting with wide complex tachycardia: a case report - Alghamdi M, Almulhim M, Bunaian A, Al-Osail E, Alhowaish A, Alabdulmhsin M, Alhawas A, Alfaraj D.
BACKGROUND: Ventricular tachycardia (VT) is an abnormal heart rhythm that can lead to pump failure and hypoperfusion. Its causes, presentation, and treatment are well established in the literature. However, the VT treatment algorithm is based on non-trauma... (Source: SafetyLit)
Source: SafetyLit - October 27, 2023 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Wide Complex Tachycardia: SVT or VT? Wide Complex Tachycardia: SVT or VT?
Treat all WCTs as ventricular tachycardia and you ' ll save lives.Medscape Emergency Medicine (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - October 17, 2023 Category: Emergency Medicine Tags: Emergency Medicine Viewpoint Source Type: news
Accidental poisoning with aconite overdose: a case report and resuscitative emergency management in a tertiary level hospital of Bangladesh - Majumder MI, Mahadi AR, Rahman OU, Roy BK, Shihab HM.
Intoxication with aconite, a common over-the-counter herbal medicine in Asia, can result in ventricular tachycardia and cardiac arrest and requires heart rate monitoring in a critical care setting and aggressive use of antiarrhythmica. Educational efforts ... (Source: SafetyLit)
Source: SafetyLit - August 30, 2023 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Impella Not Linked to Better VT Ablation Outcomes
(MedPage Today) -- NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, according to initial observational... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 22, 2023 Category: Cardiology Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
Doctors are zapping the heart with radiation in a bid to cure a common cause of cardiac arrest
Radiation normally reserved for cancer patients is being tested on 400 patients to see if it helps repair misfiring heart cells. A major cause of sudden cardiac arrest, ventricular tachycardia, is thought to be responsible for about 6 million deaths annually worldwide. The heart’s abnormally fast…#washingtonuniversity #varian #drphillipcuculich #stlouis #jeffbackus #drstaceyrentschler #drcliffordrobinson #backus #fda (Source: Reuters: Health)
Source: Reuters: Health - May 2, 2023 Category: Consumer Health News Source Type: news
A New Study Shows How Seriously Air Pollution Can Affect Your Heartbeat
For China’s 1.4 billion people, the simple act of breathing has long been something of a risk. Living in the ninth-dirtiest country in the world in terms of air quality, China’s residents lose an average of 2.6 years of life per capita due to atmospheric pollution alone. The greatest risk, of course, is pulmonary, with air pollution leading to shortness of breath, wheezing, coughing, asthma episodes, and chest pain. But pollution affects the heart too; the U.S. Environmental Protection Agency reports that exposure to fine-particulate matter as well as to nitrogen oxides alone can lead to premature aging in bloo...
Source: TIME: Health - May 1, 2023 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized climate change Climate Is Everything Environment healthscienceclimate Source Type: news
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
First-in-human trial shows promise for hard-to-treat ventricular tachycardia heart rhythms
ROCHESTER, Minn. — A first-in-human multicenter trial involving Mayo Clinic used a new ablation technique for patients with ventricular tachycardia, an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide. The trial tested needle ablation using in-catheter, heated, saline-enhance d, radio frequency energy, also known as SERF, to substantially increase heat transfer, compared to conventional ablation methods. The new process produces deeper, controllable lesion scars at sites inside the heart muscle.… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - August 2, 2022 Category: Research Source Type: news
Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Misdiagnosis in Patient With Dizziness, Leg Weakness
(MedPage Today) -- Typical parkinsonian tremor can simulate atrial flutter or ventricular tachycardia on ECG (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 31, 2022 Category: Cardiology Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
